🇨🇭 NOVN.SW — Novartis AG
Healthcare MantenerPrecio actual
129,58 CHF
Máx. histórico
132,68
1 días
Caída desde máximo
-2,34%
Rango 52 semanas
96,03 – 132,68
Variación hoy
-1,33%
Cierre anterior
131,32
Rango de hoy
129,40 – 130,86
Volumen hoy
2.616.060
- Nombre completo
- Novartis AG
- Divisa
- CHF
- Mercado
- Swiss
- Sector
- Healthcare
- Industria
- Drug Manufacturers - General
- Empleados
- 75.267
- PER ⓘ
- 24,13 (puede no estar actualizado)
- Dividend yield
- 2,86% (puede no estar actualizado)
- Precio objetivo analistas
- 125,40 CHF (puede no estar actualizado)
- Primera cotización
- 03/04/1995
- Precio actualizado
- hace 2 días
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Fecha de pago | Importe por participación |
|---|---|
| 24/02/2011 | 2,2000 CHF |
| 02/03/2010 | 2,1000 CHF |
| 27/02/2009 | 2,0000 CHF |
| 29/02/2008 | 1,6000 CHF |
| 09/03/2007 | 1,3500 CHF |
| 03/03/2006 | 1,1500 CHF |
| 04/03/2005 | 1,0500 CHF |
| 27/02/2004 | 1,0000 CHF |
| 07/03/2003 | 0,9500 CHF |
| 26/03/2002 | 0,9000 CHF |
| 27/03/2001 | 0,8500 CHF |
| 17/04/2000 | 0,8000 CHF |
| 26/04/1999 | 0,7250 CHF |
| 24/04/1998 | 0,6250 CHF |
| 25/04/1997 | 0,5000 CHF |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/03/2004 | 45,16 | 45,58 | 44,82 | 45,24 | +0,75% | 1,67% | 42.953.542 |
| 18/03/2004 | 45,41 | 45,70 | 44,87 | 44,91 | -1,29% | 1,85% | 9.817.075 |
| 17/03/2004 | 45,37 | 45,66 | 45,16 | 45,49 | +0,65% | 1,11% | 26.620.769 |
| 16/03/2004 | 45,16 | 45,37 | 44,61 | 45,20 | +0,37% | 1,67% | 9.444.430 |
| 15/03/2004 | 44,95 | 45,54 | 44,82 | 45,03 | -0,92% | 1,58% | 15.493.125 |
| 12/03/2004 | 44,53 | 45,45 | 44,03 | 45,45 | -0,09% | 3,20% | 28.446.540 |
| 11/03/2004 | 47,25 | 47,38 | 45,49 | 45,49 | -4,32% | 3,99% | 42.064.411 |
| 10/03/2004 | 46,92 | 47,71 | 46,84 | 47,55 | +1,07% | 1,87% | 10.265.333 |
| 09/03/2004 | 46,79 | 47,25 | 46,75 | 47,04 | +0,27% | 1,08% | 14.166.439 |
| 08/03/2004 | 47,13 | 47,21 | 46,92 | 46,92 | +0,00% | 0,62% | 16.901.439 |
| 05/03/2004 | 47,71 | 47,76 | 46,84 | 46,92 | -1,75% | 1,93% | 9.712.165 |
| 04/03/2004 | 47,71 | 47,80 | 47,17 | 47,76 | +0,53% | 1,32% | 7.228.924 |
| 03/03/2004 | 47,55 | 47,71 | 47,21 | 47,51 | -0,70% | 1,06% | 4.990.642 |
| 02/03/2004 | 47,51 | 47,84 | 47,34 | 47,84 | +1,06% | 1,06% | 5.709.729 |
| 01/03/2004 | 47,13 | 47,51 | 47,00 | 47,34 | +0,98% | 1,07% | 12.332.571 |
| 27/02/2004 | 46,92 | 47,25 | 46,63 | 46,88 | -1,24% | 1,34% | 16.008.309 |
| 26/02/2004 | 47,55 | 47,55 | 46,84 | 47,46 | -0,35% | 1,50% | 15.269.013 |
| 25/02/2004 | 47,42 | 47,67 | 46,96 | 47,63 | +0,44% | 1,50% | 15.613.525 |
| 24/02/2004 | 47,42 | 47,71 | 47,30 | 47,42 | -0,27% | 0,88% | 12.296.342 |
| 23/02/2004 | 47,55 | 47,88 | 47,42 | 47,55 | +0,44% | 0,97% | 6.103.050 |
| 20/02/2004 | 47,67 | 47,71 | 47,13 | 47,34 | -0,53% | 1,23% | 48.361.312 |
| 19/02/2004 | 48,01 | 48,18 | 47,38 | 47,59 | -0,35% | 1,66% | 12.153.099 |
| 18/02/2004 | 48,26 | 48,47 | 47,71 | 47,76 | -0,95% | 1,56% | 15.118.422 |
| 17/02/2004 | 48,64 | 48,76 | 48,18 | 48,22 | -1,03% | 1,21% | 31.720.279 |
| 16/02/2004 | 48,76 | 48,89 | 48,34 | 48,72 | -0,17% | 1,12% | 17.027.143 |
| 13/02/2004 | 48,85 | 48,89 | 48,30 | 48,80 | +0,43% | 1,20% | 18.815.347 |
| 12/02/2004 | 49,22 | 49,31 | 48,55 | 48,59 | -0,77% | 1,53% | 22.236.062 |
| 11/02/2004 | 48,93 | 49,26 | 48,93 | 48,97 | +0,00% | 0,68% | 10.116.079 |
| 10/02/2004 | 48,72 | 49,01 | 48,47 | 48,97 | -0,09% | 1,12% | 6.672.301 |
| 09/02/2004 | 48,89 | 49,14 | 48,76 | 49,01 | +0,34% | 0,77% | 6.841.458 |